433938-41-1

Upstream product

• 853782-50-0 (S)-3-chloro-5-difluoro-methoxy-mandelic acid 
• 433938-40-0 Ph(3-Cl)(5-OCHF₂)-(R,S)CH(OH)C(O)OEt 

Downstream Products

• 433938-42-2 (2R)-[3-chloro-5-(difluoromethoxy)-phenyl](hydroxy)acetic acid 
• 853782-50-0 (S)-3-chloro-5-difluoro-methoxy-mandelic acid 

Relevant academic research and scientific papers

A PROCESS FOR THE DYNAMIC RESOLUTION OF (SUBSTITUTED) (R) - OR (S) -MANDELIC ACID

The present invention relates to a process for the resolution of mandelic acid derivative enantiomers from (racemic) mixtures by salt formation (see, for example, formula IIa) with chiral base cyclic amides, and racemisation of the unresolved enantiomer i

NEW PROCESS

The present invention relates to a new process for the resolution of mandelic acid derivatives from racemic mandelic acid derivative mixtures by salt formation with chiral base cyclic amides; to the resolved mandelic acid cyclic amide salts (see, for exam

Mandelic acid derivatives and their use as throbin inhibitors

There is provided a compound of formula I wherein Ra, R1, R2, Y and R3 have meanings given in the description and pharmaceutically acceptable derivatives (including prodrugs) thereof, which compounds and derivatives are useful as, or are useful as prodrugs of, competitive inhibitors of trypsin-like proteases, such as thrombin, and thus, in particular, in the treatment of conditions where inhibition of thrombin is required (e.g. thrombosis) or as anticoagulants.

IMMEDIATE RELEASE PHARMACEUTICAL FORMULATION

According to the present invention there is provided an immediate release pharmaceutical formulation comprising, as active ingredient, a compound of formula (I), wherein R1 represents C?1-2#191 alkyl substituted by one or more fluoro substituen

MODIFIED RELEASE PHARMACEUTICAL FORMULATION

A modified release pharmaceutical composition comprising, as active ingredient, a compound of formula (I), wherein R1 represents C?1-2#191 alkyl substituted by one or more fluoro substituents;R2 represents hydrogen, hydroxy, methoxy

PHARMACEUTICAL COMBINATION

There is provided a combination product comprising: (1) a compound of claim 1 in WO 02/44145 or a compound of claim 20 in WO 02/44145 (or derivative thereof)or a pharmaceutically-acceptable derivative thereof; and (1) a compound as defined in claim 1 of WO 01/28992 or (2) a compound of Claim 34 of WO 01/28992 or (3) Compound A or B or C or D (or pharmaceutically-acceptable salts thereof) for use in treating arrhythmia or a coagulation controlled complication thereof.